Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy (STARTER): a Multicenter Retro-prospective Cohort Study

What this Trial Is About

Researchers are studying Arrhythmogenic Cardiomyopathy (ACM), focusing on patients diagnosed with this condition at the First Affiliated Hospital of Xi 'an Jiaotong University and other centers. The study aims to collect clinical data and biological samples from patients with different ACM types to understand the disease characteristics, development, clinical features, natural progression, and long-term outcomes. This observational study follows patients over time to explore these aspects thoroughly. Participants will be grouped based on ACM phenotype: right ventricular ACM, left ventricular ACM, or biventricular ACM, depending on which parts of the heart are affected by enlargement and fibroadipose tissue replacement. Diagnosis follows established criteria including imaging, arrhythmia patterns, histology, and family history or genetics. All participants will be observed without experimental treatment, focusing on tracking disease progression and outcomes. During the study, researchers will collect data at diagnosis, before discharge, and at multiple scheduled intervals up to three years, monitoring mortality rates and other clinical changes. Participants will undergo various diagnostic tests such as cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathology exams, and gene sequencing. Consent and authorization from patients or their families are required for participation and data use.

Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy